Company Overview - Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd. is a synthetic biology technology-driven biopharmaceutical company focused on developing innovative cancer drugs [2] - The company has developed three core technology platforms for the research and development of new drugs based on microbial metabolites [2] - The core product, Uterlon Injection, was approved for market in 2021 for treating recurrent or metastatic breast cancer in patients who have previously received at least one anthracycline or taxane chemotherapy regimen [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 71.866 million yuan, a year-on-year increase of 7.85% [1] - The net profit attributable to shareholders was -144 million yuan, showing a year-on-year increase of 24.19% [1][3] - The gross profit margin stood at 85%, with a debt-to-asset ratio of 13.41% [1] Market Position and Valuation - The company's price-to-earnings (P/E) ratio is -11.76, ranking 121st in the industry, while the average P/E ratio for the pharmaceutical and biotechnology industry is 3.78 [1] - Other companies in the industry have P/E ratios such as: Qingdao Haier Biomedical (0.85), Kingsray Biotechnology (1.44), Dongrui Pharmaceutical (3.05), Jilin Changlong Pharmaceutical (5.86), and Dajiankang International (5.97) [1] Product Pipeline - The company has one commercialized product and 19 other pipeline candidates [2] - Uterlon Injection is the only chemotherapy drug developed using synthetic biology technology that has been approved for market in China in nearly two decades [2]
华昊中天医药-B（02563.HK）7月3日收盘上涨55.09%，成交3223.42万港元